Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Editas Attracts Major Investors
by Ann M. Thayer
August 17, 2015
| A version of this story appeared in
Volume 93, Issue 32
Editas Medicine, a genome-editing therapeutics firm founded in 2013 around CRISPR/Cas9 technology, raised $120 million in a series B financing round. The funding came from investors that launched the firm with a $43 million series A round plus new investors led by Boris Nikolic, managing director of bng0, which was formed to invest exclusively in Editas. Nikolic, who until recently was chief adviser for science and technology at initiatives linked to Bill Gates, will join the Editas board of directors.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X